Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

InVivoMAb Anti-EBV/HHV4 gB/BALF4 Antibody (Iv0133)

Catalog #:   VVV22001 Specific References (54) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: Neutralization
Accession: R4R670
Overview

Catalog No.

VVV22001

Species reactivity

Epstein-Barr virus (strain GD1) (HHV-4) (Human herpesvirus 4)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Envelope glycoprotein B, gB, BALF4, gB, EBVaGC1_061

Concentration

1.2 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

R4R670

Applications

Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0133

Data Image
  • SDS-PAGE
    SDS PAGE for EBV/HHV4 gB/BALF4 Antibody (Iv0133)
References

Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. PMID: 3027378

Epstein-Barr virus genome may encode a protein showing significant amino acid and predicted secondary structure homology with glycoprotein B of herpes simplex virus 1. PMID: 2999435

Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus. PMID: 21593154

Glycoprotein 110, the Epstein-Barr virus homolog of herpes simplex virus glycoprotein B, is essential for Epstein-Barr virus replication in vivo. PMID: 8627735

A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection., PMID:40338258

Structure and Antigenicity of Kaposi's Sarcoma-Associated Herpesvirus Glycoprotein B., PMID:40285648

A Chimeric Virus-Like Particle Vaccine Presenting an Immunodominant Epitope of gB Elicited Potent Neutralizing Antibodies against EBV Infection In Vitro and In Vivo., PMID:40272901

An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus., PMID:39499444

Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice., PMID:39346922

GB and gH/gL fusion machinery: a promising target for vaccines to prevent Epstein-Barr virus infection., PMID:39020055

Cytomegalovirus, Epstein-Barr Virus, Herpes Simplex Virus, and Varicella Zoster Virus Infection Dynamics in People with Multiple Sclerosis from Northern Italy., PMID:38921797

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection., PMID:38906867

Twenty-four Month Outcomes of Extended- Versus Standard-course Antibiotic Therapy in Children Hospitalized With Pneumonia in High-risk Settings: A Randomized Controlled Trial., PMID:38830139

Evaluation of serum Epstein-Barr virus envelope glycoproteins antibodies and their association with systemic autoimmune diseases., PMID:38587217

Fully Human Herpesvirus-Specific Neutralizing IgG Antibodies Generated by EBV Immortalization of Splenocytes-Derived from Immunized Humanized Mice., PMID:38201224

A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV., PMID:37848029

Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma., PMID:36519117

Urgency and necessity of Epstein-Barr virus prophylactic vaccines., PMID:36494369

Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion., PMID:35917353

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells., PMID:35711430

Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective., PMID:35493498

Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses., PMID:35404082

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases., PMID:34691042

Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge., PMID:33808755

Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients., PMID:33493797

Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma., PMID:33268566

A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits., PMID:32268575

Predictors of Epstein-Barr virus serostatus in young people in England., PMID:31779585

Epstein-Barr virus infection with acute acalculous cholecystitis in previously healthy children., PMID:31243873

Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology., PMID:30727744

Acidic pH Mediates Changes in Antigenic and Oligomeric Conformation of Herpes Simplex Virus gB and Is a Determinant of Cell-Specific Entry., PMID:29925660

An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus., PMID:29669253

Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry., PMID:29292383

Inhibition of EBV-mediated membrane fusion by anti-gHgL antibodies., PMID:28939750

Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice., PMID:27926486

Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome., PMID:27878471

Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350., PMID:27291087

Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination., PMID:27096949

Scanning Mutagenesis of Human Cytomegalovirus Glycoprotein gH/gL., PMID:26656708

Crystal Structure of the Human Cytomegalovirus Glycoprotein B., PMID:26484870

Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism., PMID:26085146

The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation., PMID:25506120

Herpes virus fusion and entry: a story with many characters., PMID:22754650

Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL., PMID:21957301

Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus., PMID:21593154

Structure of a core fragment of glycoprotein H from pseudorabies virus in complex with antibody., PMID:21149698

Infection of porcine cells with human herpesviruses., PMID:20692426

Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8., PMID:19920174

Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa., PMID:19774687

Viral reactivation is not related to septic complications after major surgical resections., PMID:18397464

Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion., PMID:17307213

Identification of tear lipocalin as a novel autoantigen target in Sjögren's syndrome., PMID:16249071

Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells., PMID:16103144

Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins., PMID:15583133

Datasheet
$ 372
Product specifications
100 μg 372 1 mg 1486

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

InVivoMAb Anti-EBV/HHV4 gB/BALF4 Antibody (Iv0133) [VVV22001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only